Nanomedicine firm Nanobiotix, a spinoff from the University of Buffalo, raises $18.1m in its initial public offering.
Nanobiotix, a France-based nanomedicine spinoff from the University of Buffalo (UB), has raised €14.2m ($18.1m) in its initial public offering. Trading under the ticker code “NANO” on the NYSE Euronext, the Paris-based firm is trading 8,053,880 existing shares and 2,361,607 new shares at an issue price set at €6 a share. Market capitalisation was around…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
